Anyone who tuned into Allergan’s Q1 earnings call hoping for signs of big M&A to come likely left disappointed.

Is Pfizer thinking of buying Bristol-Myers Squibb, as the rumors go? CEO Ian Read hinted at the possibility on Tuesday's Q1 earnings call.

Swedish CDMO Recipharm’s growing global footprint in 2016 has positioned the company to take advantage of what is expected to be more consolidation and growth…

Growth in the generic sterile manufacturing industry has spawned a series of big buyouts in the last few years, and Germany’s Fresenius is looking to M&A…

Nigeria has been looking for ways to get more drugs manufactured in the country while Servier’s generics unit Biogaran has been looking to expand. Now both…

The market for hepatitis C drugs is shrinking. Shortly after spending $3.9 billion on Idenix, Merck is taking a $2.9 billion hit on an experimental compound.

Sun Pharma’s Ranbaxy unit has started work on a manufacturing plant in Egypt, a project that got under way well before Sun bought Ranbaxy in 2015.

India’s Granules will do a significant expansion of its API bulk drug site in Vishakhapatnam, and is getting substantial help from the International Finance…

M&A